TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37161377

Group type: EXPERIMENTAL
Intervention: Single-dose MR-guided partial breast irradiation (PBI) with a prescribed dose of 20 Gy to the tumor and 15 Gy to the surrounding breast tissue.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single-dose MR-guided partial breast irradiation (PBI)
Number of subjects: 100
Study: 37161534

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 37161555

Group type: EXPERIMENTAL
Intervention: Nutrition optimisation family-centred intervention
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Decision support family-centred intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 37161571

Group type: EXPERIMENTAL
Intervention: Bedaquiline (400-800 mg) and Rifampicin (150-600 mg)
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Rifampicin (150-600 mg)
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Rifampicin only for contacts aged two to four years
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Molecular surveillance for resistance to rifampicin and/or bedaquiline
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Anti-M. leprae PGL-I IgM seropositivity assessment
Number of subjects: 17000
Study: 37161672

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 370

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 370
Study: 37161678

Group type: EXPERIMENTAL
Intervention: Endurance-trained premenopausal females
Number of subjects: 42
Study: 37161775

Group type: EXPERIMENTAL
Intervention: Statin and high-intensity statin (used in 72.4% of patients)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 758
Study: 37161796

Group type: COMPARATOR
Intervention: DASH diet (serum)
Number of subjects: 614

Group type: COMPARATOR
Intervention: DASH high-sodium diet (urine)
Number of subjects: 614

Group type: COMPARATOR
Intervention: DASH low-sodium diet (urine)
Number of subjects: 614
Study: 37161823

Group type: EXPERIMENTAL
Intervention: High-Intensity Lipid-Lowering Therapies
Number of subjects: 0
Study: 37162000

Group type: EXPERIMENTAL
Intervention: Mobile application designed to support patients with insulin therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 32
Study: 37162147

Group type: EXPERIMENTAL
Intervention: 3 mg of plecanatide
Number of subjects: 2639

Group type: EXPERIMENTAL
Intervention: 6 mg of plecanatide
Number of subjects: 2639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2639
Study: 37162238

Group type: EXPERIMENTAL
Intervention: ZILVER PTX stent
Number of subjects: 220

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 220
Study: 37162250

Group type: EXPERIMENTAL
Intervention: Prehabilitation (four-week trimodal programme: exercise, nutritional intervention, anxiety reduction)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Prehabilitation (four-week trimodal programme)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 250
Study: 37162301

Group type: EXPERIMENTAL
Intervention: Recreational team handball exercise programme
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 37162349

Group type: EXPERIMENTAL
Intervention: Vancomycin intravenously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Model-based simulations of various infusion modes
Number of subjects: 14
Study: 37162539

Group type: EXPERIMENTAL
Intervention: Arthroscopic modified Broström procedure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open modified Broström procedure
Number of subjects: 64
Study: 37162595

Group type: EXPERIMENTAL
Intervention: Phenotypes with prominent geriatric features
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Phenotype representing the oldest old patients with low severity of the critical condition
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Logistic regression models combining phenotype, ventilatory support, and country
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Decisions to withhold LST
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Decisions to withdraw LST
Number of subjects: 1268
Study: 37162700

Group type: COMPARATOR
Intervention: Cognitive training and physical exercise (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 37162744

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg every 4 weeks until week 24
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo every 4 weeks until week 24
Number of subjects: 101
Study: 37162745

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 24861
Study: 37162923

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection during pregnancy
Number of subjects: 2300
Study: 37163146

Group type: EXPERIMENTAL
Intervention: EZC Pak
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: EZC Pak + Vitamin D
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 37163204

Group type: EXPERIMENTAL
Intervention: Pressure Release Technique (PRT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham PRT (Control)
Number of subjects: 72
Study: 37163222

Group type: EXPERIMENTAL
Intervention: Rilonacept (Arcalyst)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret)
Number of subjects: 0
Study: 37163240

Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defects
Number of subjects: 2507

Group type: COMPARATOR
Intervention: Nonclosure
Number of subjects: 2507
Study: 37163249

Group type: EXPERIMENTAL
Intervention: Specialist palliative care intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 235
Study: 37163331

Group type: EXPERIMENTAL
Intervention: Standard implementation intervention (multimodal training for coaches, organizational strategy meetings)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enhanced implementation intervention (includes all standard strategies plus performance coaching)
Number of subjects: 72
Study: 37163341

Group type: EXPERIMENTAL
Intervention: Immersive telemedicine platform for diabetes medical group visits (DMGVs)
Number of subjects: 309

Group type: COMPARATOR
Intervention: In-person (IP) diabetes medical group visits (DMGVs)
Number of subjects: 309
Study: 37163342

Group type: EXPERIMENTAL
Intervention: Sensor-Controlled Digital Game (SCDG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sensor-only group (control)
Number of subjects: 200
Study: 37163349

Group type: EXPERIMENTAL
Intervention: PTCy, abatacept, and a short course of tacrolimus (CAST)
Number of subjects: 46
Study: 37163350

Group type: EXPERIMENTAL
Intervention: Patient-Oriented Music Intervention (POMI) using music based on patient preferences via headphones or music pillow for 20-30 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control intervention (headphones or pillow without music)
Number of subjects: 24
Study: 37163358

Group type: EXPERIMENTAL
Intervention: Carfilzomib, daratumumab, and dexamethasone (KdD)
Number of subjects: 0
Study: 37163360

Group type: EXPERIMENTAL
Intervention: Anthracycline-based regimens
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Radiotherapy (RT)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (RT)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: SALENTO Model (Limited Stage Peripheral T-Cell Lymphoma Prognostic Model)
Number of subjects: 211
Study: 37163435

Group type: COMPARATOR
Intervention: VAN-Visual Network (VN) connectivity in normal cognition (NC) group (n = 106)
Number of subjects: 139

Group type: COMPARATOR
Intervention: VAN-Visual Network (VN) connectivity in cognitive non-decline (CND) group (n = 113)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: VAN-VN connectivity
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: VAN-VN connectivity in normal cognition participants
Number of subjects: 139
Study: 37163621

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab-ibrutinib
Number of subjects: 926

Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab
Number of subjects: 926
Study: 37163622

Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy delivered by means of a peanut patch for 12 months
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo administered daily for 12 months
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy delivered by means of a peanut patch
Number of subjects: 362
Study: 37163623

Group type: EXPERIMENTAL
Intervention: Cabozantinib (40 mg daily) plus nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab and ipilimumab
Number of subjects: 855

Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab
Number of subjects: 855
Study: 37163686

Group type: EXPERIMENTAL
Intervention: Buzzy device
Number of subjects: 300

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 300
Study: 37163774

Group type: EXPERIMENTAL
Intervention: Rezivertinib (≥180 mg orally once daily)
Number of subjects: 355
Study: 37164012

Group type: EXPERIMENTAL
Intervention: BNT162b4 (mRNA vaccine targeting conserved non-spike antigens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNT162b2 (spike-protein-encoding vaccine)
Number of subjects: 0
Study: 37164298

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including oncology clinic-based oncofertility needs screen, women's health survivorship care plan in Spanish and English, remote patient navigation, telehealth oncofertility consultation.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care during the pre-intervention period (12 months).
Number of subjects: 135
Study: 37164457

Group type: EXPERIMENTAL
Intervention: Monthly follow-up by a community-based stroke coordinator who identifies individual risk profiles and sets up action plans based on individual goals.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Monthly follow-up by a community-based stroke coordinator.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 300
Study: 37164461

Group type: EXPERIMENTAL
Intervention: Multicomponent provider-patient intervention (patient mHealth app, provider dashboard, continuous glucose monitoring, community health worker, team-based care)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Current standard of diabetes and prenatal care
Number of subjects: 124
Study: 37164465

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 37164467

Group type: EXPERIMENTAL
Intervention: Low iodine (20 µg/day) multivitamin and mineral supplement
Number of subjects: 754

Group type: COMPARATOR
Intervention: Identical supplement containing 200 µg/day
Number of subjects: 754
Study: 37164469

Group type: EXPERIMENTAL
Intervention: Neurological and cognitive impairments assessed using validated clinical assessment methods
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Blood samples for biomarker measuring (protein, RNA and DNA)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Clinical variables registered at baseline and each follow-up visit
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Identification of recurrent stroke and other major vascular events
Number of subjects: 500
Study: 37164472

Group type: EXPERIMENTAL
Intervention: GBDPs group (treatment group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo group (control group)
Number of subjects: 72
Study: 37164478

Group type: EXPERIMENTAL
Intervention: Chronic ankle instability at 12-month follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost diary containing direct and indirect costs related to their injury
Number of subjects: 0
Study: 37164490

Group type: EXPERIMENTAL
Intervention: Knowledge translation program of guidelines
Number of subjects: 45193

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45193
Study: 37164620

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (HBET) programme
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care (CONTROL)
Number of subjects: 50
Study: 37164838

Group type: EXPERIMENTAL
Intervention: Inclisiran 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37164837

Group type: COMPARATOR
Intervention: Volanesorsen
Number of subjects: 3
Study: 37164948

Group type: EXPERIMENTAL
Intervention: Sitravatinib plus nivolumab
Number of subjects: 20
Study: 37164957

Group type: EXPERIMENTAL
Intervention: Ansofaxine 80 mg/day
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Ansofaxine 160 mg/day
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 37164959

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intranasal followed by intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91
Study: 37165291

Group type: EXPERIMENTAL
Intervention: Rasburicase 0.20 mg/kg/day
Number of subjects: 50
Study: 37165331

Group type: EXPERIMENTAL
Intervention: Leadership training comprising five full day modules and four smaller group-training sessions over a period of 5 months.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Leadership training intervention.
Number of subjects: 200
Study: 37165382

Group type: EXPERIMENTAL
Intervention: Hypertension plus practice facilitation (experimental condition)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Hypertension program only (usual care)
Number of subjects: 960
Study: 37165406

Group type: EXPERIMENTAL
Intervention: Stress Arousal Reappraisal (SAR)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Worked Examples (WE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group for SAR
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group for WE
Number of subjects: 200
Study: 37165413

Group type: COMPARATOR
Intervention: Median benchmark, benefit framing
Number of subjects: 267

Group type: COMPARATOR
Intervention: Top quartile benchmark, benefit framing
Number of subjects: 267

Group type: COMPARATOR
Intervention: Median benchmark, risk framing
Number of subjects: 267

Group type: COMPARATOR
Intervention: Top quartile benchmark, risk framing
Number of subjects: 267
Study: 37165711

Group type: EXPERIMENTAL
Intervention: Gradual weaning of EVD treatment (multi-step increase of resistance over days)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Prompt closure of EVD treatment
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Gradual weaning of EVD treatment
Number of subjects: 244
Study: 37165841

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37165840

Group type: EXPERIMENTAL
Intervention: Zinpentraxin alfa (RO7490677, PRM-151) administered intravenously weekly (QW) or every 4 weeks (Q4W)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Zinpentraxin alfa
Number of subjects: 27
Study: 37165867

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37165869

Group type: EXPERIMENTAL
Intervention: Intensive SBP intervention (<120 mm Hg)
Number of subjects: 8298

Group type: COMPARATOR
Intervention: Standard SBP intervention (<140 mm Hg)
Number of subjects: 8298
Study: 37165897

Group type: EXPERIMENTAL
Intervention: Assessment of RNA splicing in CHD cases with splice-altering variants
Number of subjects: 4472
Study: 37165901

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) assessment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance measurements
Number of subjects: 82
Study: 37165930

Group type: EXPERIMENTAL
Intervention: TNX-102 SL 2.8 mg for 2 weeks, followed by 5.6 mg for 12 weeks
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Number of subjects: 503
Study: 37165977

Group type: EXPERIMENTAL
Intervention: Septal myectomy for HOCM
Number of subjects: 56
Study: 37166022

Group type: EXPERIMENTAL
Intervention: HINTS (for clinicians trained in its use) in patients with nystagmus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finger rub
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severity of gait unsteadiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain computed tomography (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine magnetic resonance imaging (MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Search for symptoms or signs of cerebral ischemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT angiography or MRI angiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dix-Hallpike test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 0
Study: 37166053

Group type: EXPERIMENTAL
Intervention: PEP503 (NBTXR3) nanoparticles with radiotherapy and concurrent chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (preoperative concurrent chemoradiotherapy)
Number of subjects: 0
Study: 37166151

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (600 mg of calcium plus 200 UI of cholecalciferol)
Number of subjects: 56
Study: 37166199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study: 37166242

Group type: EXPERIMENTAL
Intervention: Under-the-nose face mask (FM)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Over-the-nose face mask (FM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 37166257

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dexamethasone 0.3 mg/kg
Number of subjects: 160
Study: 37166385

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at Week 0, Week 4, and every 12 weeks thereafter
Number of subjects: 55
Study: 37166484

Group type: EXPERIMENTAL
Intervention: Tislelizumab + DNA hypomethylating agent (HMA) + CAG regimen
Number of subjects: 27
Study: 37166557

Group type: EXPERIMENTAL
Intervention: High baseline ctDNA CNA burden
Number of subjects: 672

Group type: COMPARATOR
Intervention: pCR(+) and low I-score
Number of subjects: 672

Group type: COMPARATOR
Intervention: non-pCR and high I-score
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: LP-WGS ctDNA CNA analysis
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: ctDNA CNA burden
Number of subjects: 672
Study: 37166675

Group type: EXPERIMENTAL
Intervention: MG Symptoms Patient-Reported Outcome (PRO)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Quantitative MG (QMG)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MG Composite (MGC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MG-Activities of Daily Living (MG-ADL)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MG Symptoms PRO
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Rasch model analyses
Number of subjects: 43
Study: 37166786

Group type: EXPERIMENTAL
Intervention: Swab pressing
Number of subjects: 126

Group type: COMPARATOR
Intervention: Stromal hydration
Number of subjects: 126
Study: 37166798

Group type: EXPERIMENTAL
Intervention: Diffusing alpha-emitter radiation therapy (DaRT) with a physical dose of 10 Gy (equivalent weighted dose of 200 CGE) to the tumor.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DaRT procedure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) monitoring
Number of subjects: 10
Study: 37166817

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) plus trastuzumab and pertuzumab
Number of subjects: 207

Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab and pertuzumab
Number of subjects: 207
Study: 37166851

Group type: EXPERIMENTAL
Intervention: Time-limited PCIT
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Time-limited CPP
Number of subjects: 144
Study: 37166948

Group type: EXPERIMENTAL
Intervention: Memantine as an augmentative agent to a selective serotonin reuptake inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37166961

Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate (VLC) diet intervention
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Daily dietary self-monitoring
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Monthly dietary self-monitoring
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mindful eating
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Positive affect skills training
Number of subjects: 112
Study: 37166980

Group type: EXPERIMENTAL
Intervention: FED (participants ate breakfast and lunch)
Number of subjects: 12

Group type: COMPARATOR
Intervention: FAST (participants remained fasted)
Number of subjects: 12
Study: 37166995

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) with progressive weight loss (6%, 11%, 16%) in people without diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB) in people without diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) in people without diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or low-calorie diet (LCD) in people with diabetes
Number of subjects: 0
Study: 37166997

Group type: EXPERIMENTAL
Intervention: Small-molecule activator of PP2A (SMAP, DT-061)
Number of subjects: 0
Study: 37167078

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no MOP)
Number of subjects: 28
Study: 37167165

Group type: EXPERIMENTAL
Intervention: Ergoferon (1 tablet, 2 times a day for 3 weeks)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057